Enanta Pharmaceuticals
ENTA
122 hedge funds and large institutions have $454M invested in Enanta Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 38 increasing their positions, 45 reducing their positions, and 17 closing their positions.
23% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $1.05M
15% more capital invested
Capital invested by funds: $396M → $454M (+$58.2M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.36% less ownership
Funds ownership: 67.47% → 66.11% (-1.4%)
3% less funds holding
Funds holding: 126 → 122 (-4)
16% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 45
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$9.82M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.53M |
| 3 |
IG
ING Group
Amsterdam,
Netherlands
|
+$2.91M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.3M |
| 5 |
First Manhattan
New York
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$8.07M |
| 2 |
GTC
Ghost Tree Capital
New York
|
-$3.2M |
| 3 |
SIM
Spark Investment Management
New York
|
-$3.14M |
| 4 |
BlackRock
New York
|
-$3.09M |
| 5 |
MCM
Matarin Capital Management
New York
|
-$2.27M |
ENTA Hedge Fund Activity: Q2 2017 in Review
122 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q2 2017, worth a combined $454M — up 15% from $396M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ENTA and 13 opened new positions — a net loss of 4 holders — while 45 trimmed existing stakes and 38 added.
The largest buyer was Stonepine Capital Management, adding an estimated $9.82M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $8.07M sold.
- 122 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q2 2017, down from 126 in Q1 2017.
- Funds reported $454M of Enanta Pharmaceuticals stock for Q2 2017, up 15% quarter-over-quarter.
- 13 funds opened new Enanta Pharmaceuticals positions in Q2 2017 and 17 closed out, a net change of -4 holders.
- The largest Enanta Pharmaceuticals buyer in Q2 2017 was Stonepine Capital Management, an estimated $9.82M added.
- The largest Enanta Pharmaceuticals seller in Q2 2017 was Acadian Asset Management, an estimated $8.07M sold.
Based on aggregated 13F filings for Q2 2017.